Table 2.
Clinical and radiological findings among the 3 groups after switch
| Variables° | OCR (64) | RTX (36) | CLA (20) | p* |
|---|---|---|---|---|
| Patients relapsing during treatment n (%) | 5 (7.8) | 5 (13.9) | 4 (20) | ns |
| Patients with more than 1 relapse during treatment n (%) | 0 | 3 (8.3) | 3 (15) | 0.017 |
| Median time to first relapse median (q1–q3) (months) | 3 (2–3) | 6 (3–8) | 3 (2.7–3.7) | ns |
| EDSS at baseline median (q1–q3) | 3.0 (2.0–4.5) | 4.0 (2.0–4.5) | 2.0 (1.0–3.0) | ns |
| EDSS after 6 months median (q1–q3) | 3.0 (2.0–4.5) | 4.0 (2.0–4.5) | 2.0 (1.0–4.0) | ns |
| EDSS after 12 months median (q1–q3) | 3.0 (2.0–4.5) | 3.5 (1.5–4.0) | 3.0 (1.5–5.0) | ns |
| EDSS after 18 months median (q1–q3) | 3.0 (2.0–4.5) | 3.5 (1.5–4.0) | 3.0 (1.5–5.0) | ns |
| Patients with CDP at last follow-up n (%) | 5 (7.8) | 3 (8.3) | 2 (10) | ns |
| Patients with increased lesions load on T2-weighted or T1 Gad + weighted brain MRI lesions after 6 months n (%) | 5 (7.8) | 3 (8.3) | 4 (20) | ns |
| Patients with increased lesions load on T2-weighted or T1 Gad + weighted brain MRI lesions after 12 months n (%)** | 6 (9.3) | 6 (16.7) | 4 (20) | ns |
| Follow-up in months median (q1–q3) | 18 (15–19) | 17 (14–20) | 16 (13–18) | ns |